HUTCHMED (China) (CHIX:HCML) 3-Year RORE % : 58.96% (As of Dec. 2025)


CHIX:HCML HUTCHMED (China) Ltd CHIX:HCML
60 GF Score
Price £1.67
GF Value £2.24
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is HUTCHMED (China) 3-Year RORE %?

HUTCHMED (China) CHIX:HCML 60 3-Year RORE % is 58.96 as of Dec. 2025. GuruFocus rates CHIX:HCML with a GF Score™ of 60/100 and a GF Value™ of £2.24 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 939 Drug Manufacturers companies, HUTCHMED (China) ranks better than 85.09% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. HUTCHMED (China)'s 3-Year RORE % for the quarter that ended in Dec. 2025 was 58.96%.

The industry rank for HUTCHMED (China)'s 3-Year RORE % or its related term are showing as below:

CHIX:HCMl's 3-Year RORE % is ranked better than
85.09% of 939 companies
in the Drug Manufacturers industry
Industry Median: 3.06 vs CHIX:HCMl: 58.96

HUTCHMED (China)  (CHIX:HCMl) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


HUTCHMED (China) 3-Year RORE % Related Terms


HUTCHMED (China) 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for HUTCHMED (China)'s 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HUTCHMED (China) 3-Year RORE % Chart

HUTCHMED (China) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.26 31.70 -60.40 -165.09 58.96

HUTCHMED (China) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.40 -61.30 -165.09 143.61 58.96

CHIX:HCML vs ZTS, UTHR, VTRS: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HUTCHMED (China) 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where HUTCHMED (China)'s 3-Year RORE % falls into.


CHIX:HCML
60GF Score
HUTCHMED (China) Ltd CHIX:HCML
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HUTCHMED (China) 3-Year RORE % Calculation

HUTCHMED (China)'s 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.383-0.087 )/( 0.502-0 )
=0.296/0.502
=58.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 58.96 mean?
HUTCHMED (China) (CHIX:HCML) has a 3-Year RORE % of 58.96 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on HUTCHMED (China) and its competitors. According to the industry distribution chart, HUTCHMED (China) ranks #140 out of 939 companies in the Drug Manufacturers industry, placing it in the top 14.9%.
Is HUTCHMED (China)'s 3-Year RORE % too high?
HUTCHMED (China)'s current 3-Year RORE % is 58.96. The Drug Manufacturers industry median 3-Year RORE % is 3.06. HUTCHMED (China)'s value of 58.96 is 1826.8% above this industry median. Based on the distribution chart, HUTCHMED (China) ranks #140 out of 939 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #140 out of 939 companies for 3-Year RORE %. This places HUTCHMED (China) in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.06. HUTCHMED (China)'s value of 58.96 is 1826.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.06, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current 3-Year RORE % of 58.96 is 1826.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current 3-Year RORE % is 58.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
Based on GuruFocus' analysis, HUTCHMED (China) (CHIX:HCML) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.24, compared to a current price of £1.67 — trading 25.4% below its estimated fair value. The current 3-Year RORE % is 58.96 and 1826.8% above the Drug Manufacturers industry median of 3.06. HUTCHMED (China)'s overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For HUTCHMED (China) (CHIX:HCML), the current 3-Year RORE % is 58.96 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HUTCHMED (China) (CHIX:HCML) Overvalued in 2026?

Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued. The current stock price of £1.67 is trading 25.4% below its estimated GF Value™ of £2.24. GuruFocus considers HUTCHMED (China) to be Modestly Undervalued.

Key valuation signals for CHIX:HCML:

  • 3-Year RORE %: 58.96
  • GF Value™: £2.24 vs. price of £1.67 (25.4% below fair value)
  • GF Score™: 60/100 with 8 warning signs
  • Industry Position: 1826.8% above the Drug Manufacturers median (#140 of 939)

No single metric tells the full story. See the CHIX:HCML stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HUTCHMED (China) Business Description

Address 2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
60GF Score

Get the complete analysis for CHIX:HCML

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.67
Price
£2.24
GF Value